Macrocyclic antiproliferation agents and methods of treatment
The instant invention describes macrocyclic compounds having antiproliferation activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders.
1. A pharmaceutical composition comprising a compound of Formula I and a pharmaceutically acceptable carrier:
wherein:
each R 1 is independently H, or alkyl or aryl, each optionally substituted;
each R 2 is independently H, or alkyl or aryl, each optionally substituted;
each R 3 is independently H, or alkyl or aryl, each optionally substituted;
each R 4 is independently H, or alkyl or aryl, each optionally substituted;
each R 5 is independently H, or alkyl or aryl, each optionally substituted;
each R 6 is independently H, or alkyl or aryl, each optionally substituted;
each R 7 is independently H, or alkyl, hydroxyl, alkoxy, halo, cyano, nitro, mercapto, thioalkoxy, alkoxycarbonyl, carboxyl, amino, mono- or di-alkylamino, or amido, each optionally substituted;
each R 8 is independently H, or alkyl, hydroxyl, alkoxy, halo, cyano, nitro, mercapto, thioalkoxy, alkoxycarbonyl, carboxyl, amino, mono- or di-alkylamino, or amido, each optionally substituted;
each n is independently 1, 2, 3 or 4;
and pharmaceutically acceptable salts, solvate, or hydrate thereof;
wherein said composition comprimises at least one of the group consisting of sodium carboxymethylcelluose, propylene glycol, polyethylene glycol, and sodium lauryl sulfate.
2. The pharmaceutical composition of claim 1 , wherein the compound of Formula I is any of Compounds 1-2 in the table below:
Cmpd No.
R 1
R 2
R 3
R 4
R 5
R 6
1
i-Pr
Me
Me
CH 3 CH(OH)—
i-Bu
Et
2
i-Pr
H
Me
CH 3 CH(OH)—
i-Bu
Et.
3. The pharmaceutical composition of claim 2 further comprising an additional therapeutic agent.
4. The pharmaceutical composition of claim 3 wherein the additional therapeutic agent is an anti-cancer agent, chemotherapeutic agent, an anti-angiogenesis agent, cytotoxic agent, or an anti-proliferation agent.
5. A kit comprising an effective amount of the composition of claim 1 , in unit dosage form, together with instructions for administering the composition to a subject suffering from or susceptible to a cell proliferation disorder.